Oculis raises $15.7m in extension to B round, licenses new antibody

In two press releases today, Iceland founded Oculis Pharma announces an extension to their Series B round amounting to $15.7m (15.5m CHF), and an expansion to … Continue reading Oculis raises $15.7m in extension to B round, licenses new antibody